Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Language
Publication year range
1.
Preprint in English | bioRxiv | ID: ppbiorxiv-521129

ABSTRACT

While the protective role of neutralising antibodies against COVID-19 is well-established, questions remain about the relative importance of cellular immunity. Using 6 pMHC-multimers in a cohort with early and frequent sampling we define the phenotype and kinetics of recalled and primary T cell responses following Delta or Omicron breakthrough infection. Recall of spike-specific CD4+ T cells was rapid, with cellular proliferation and extensive activation evident as early as 1 day post-symptom onset. Similarly, spike-specific CD8+ T cells were rapidly activated but showed variable levels of expansion. Strikingly, high levels of SARS-CoV-2-specific CD8+ T cell activation at baseline and peak were strongly correlated with reduced peak SARS-CoV-2 RNA levels in nasal swabs and accelerated clearance of virus. Our study demonstrates rapid and extensive recall of memory T cell populations occurs early after breakthrough infection and suggests that CD8+ T cells contribute to the control of viral replication in breakthrough SARS-CoV-2 infections.

2.
Sydney C Morgan; Stefan Aigner; Catelyn Anderson; Pedro Belda-Ferre; Peter De Hoff; Clarisse A Marotz; Shashank Sathe; Mark Zeller; Noorsher Ahmed; Xaver Audhya; Nathan A Baer; Tom Barber; Bethany Barrick; Lakshmi Batachari; Maryann Betty; Steven M Blue; Brent Brainard; Tyler Buckley; Jamie Case; Anelizze Castro-Martinez; Marisol Chacon; Willi Cheung; LaVonnye Chong; Nicole G Coufal; Evelyn S Crescini; Scott DeGrand; David P Dimmock; J Joelle Donofrio-Odmann; Emily R Eisner; Mehrbod Estaki; Lizbeth Franco Vargas; Michele Freddock; Robert M Gallant; Andrea Galmozzi; Nina J Gao; Sheldon Gilmer; Edyta M Grzelak; Abbas Hakim; Jonathan Hart; Charlotte Hobbs; Greg Humphrey; Nadja Ilkenhans; Marni Jacobs; Christopher A Kahn; Bhavika K Kapadia; Matthew Kim; Sunil Kurian; Alma L Lastrella; Elijah S Lawrence; Kari Lee; Qishan Liang; Hanna Liliom; Valentina Lo Sardo; Robert Logan; Michal Machnicki; Celestine G Magallanes; Clarence K Mah; Denise Malacki; Ryan J Marina; Christopher Marsh; Natasha K Martin; Nathaniel L Matteson; Daniel J Maunder; Kyle McBride; Bryan McDonald; Daniel McDonald; Michelle McGraw; Audra R Meadows; Michelle Meyer; Amber L Morey; Jasmine R Mueller; Toan T Ngo; Julie Nguyen; Viet Nguyen; Laura J Nicholson; Alhakam Nouri; Victoria Nudell; Eugenio Nunez; Kyle O'Neill; R Tyler Ostrander; Priyadarshini Pantham; Samuel S Park; David Picone; Ashley Plascencia; Isaraphorn Pratumchai; Michael Quigley; Michelle Franc Ragsac; Andrew C Richardson; Refugio Robles-Sikisaka; Christopher A Ruiz; Justin Ryan; Lisa Sacco; Sharada Saraf; Phoebe Seaver; Leigh Sewall; Elizabeth W Smoot; Kathleen M Sweeney; Chandana Tekkatte; Rebecca Tsai; Holly Valentine; Shawn Walsh; August Williams; Min Yi Wu; Bing Xia; Brian Yee; Jason Z Zhang; Kristian G Andersen; Lauge Farnaes; Rob Knight; Gene W Yeo; Louise C Laurent.
Preprint in English | medRxiv | ID: ppmedrxiv-21257885

ABSTRACT

BackgroundSuccessful containment strategies for SARS-CoV-2, the causative virus of the COVID-19 pandemic, have involved widespread population testing that identifies infections early and enables rapid contact tracing. In this study, we developed a rapid and inexpensive RT- qPCR testing pipeline for population-level SARS-CoV-2 detection, and used this pipeline to establish a clinical laboratory dedicated to COVID-19 testing at the University of California San Diego (UCSD) with a processing capacity of 6,000 samples per day and next-day result turnaround times. Methods and findingsUsing this pipeline, we screened 6,786 healthcare workers and first responders, and 21,220 students, faculty, and staff from UCSD. Additionally, we screened 6,031 preschool-grade 12 students and staff from public and private schools across San Diego County that remained fully or partially open for in-person teaching during the pandemic. Between April 17, 2020 and February 5, 2021, participants provided 161,582 nasal swabs that were tested for the presence of SARS-CoV-2. Overall, 752 positive tests were obtained, yielding a test positivity rate of 0.47%. While the presence of symptoms was significantly correlated with higher viral load, most of the COVID-19 positive participants who participated in symptom surveys were asymptomatic at the time of testing. The positivity rate among preschool-grade 12 schools that remained open for in-person teaching was similar to the positivity rate at UCSD and lower than that of San Diego County, with the children in private schools being less likely to test positive than the adults at these schools. ConclusionsMost schools across the United States have been closed for in-person learning for much of the 2020-2021 school year, and their safe reopening is a national priority. However, as there are no vaccines against SARS-CoV-2 currently available to the majority of school-aged children, the traditional strategies of mandatory masking, physical distancing, and repeated viral testing of students and staff remain key components of risk mitigation in these settings. The data presented here suggest that the safety measures and repeated testing actions taken by participating healthcare and educational facilities were effective in preventing outbreaks, and that a similar combination of risk-mitigation strategies and repeated testing may be successfully adopted by other healthcare and educational systems.

3.
Antimicrob Agents Chemother ; 55(7): 3624-6, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21576427

ABSTRACT

The recommended treatment for herpes simplex encephalitis (HSE) remains intravenous acyclovir. In resource-poor countries, however, intravenous formulations are usually unavailable or unaffordable. We report the penetration of acyclovir into the cerebrospinal fluid (CSF) in patients with HSE, treated with the oral prodrug valacyclovir at 1,000 mg three times daily. The oral therapy achieved adequate acyclovir concentrations in the CSF and may be an acceptable early treatment for suspected HSE in resource-limited settings.


Subject(s)
Acyclovir/analogs & derivatives , Antiviral Agents/pharmacokinetics , Encephalitis, Herpes Simplex/drug therapy , Valine/analogs & derivatives , Acyclovir/blood , Acyclovir/cerebrospinal fluid , Acyclovir/pharmacokinetics , Acyclovir/therapeutic use , Antiviral Agents/blood , Antiviral Agents/cerebrospinal fluid , Antiviral Agents/therapeutic use , Encephalitis, Herpes Simplex/blood , Female , Humans , Male , Valacyclovir , Valine/blood , Valine/cerebrospinal fluid , Valine/pharmacokinetics , Valine/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...